Davis Polk advised the representatives of the underwriters in connection with the $122.4 million public offering of 4,800,000 shares of common stock by Flexion Therapeutics, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “FLXN.” 

Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis. 

The Davis Polk corporate team included partner John B. Meade and associates Dan Gibbons and Yoojin L. Kim. The tax team included partner Lucy W. Farr and associate Yixuan Long. Counsel David R. Bauer and associate Jay Frankel provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office. 

Copy link to share post